Results 231 to 240 of about 49,720 (263)

Tipifarnib in acute myeloid leukemia

Drugs of Today, 2007
Treatment of older patients with acute myeloid leukemia (AML) represents a significant challenge. There is little evidence that outcomes are improving for patients subjected to conventional intensive treatment. In addition, there is a large population of patients who are not considered fit for a more intensive treatment approach, and treatment options ...
Alan K, Burnett, Jonathan, Kell
openaire   +2 more sources

Adult Acute Myeloid Leukemia

Mayo Clinic Proceedings, 2006
Acute myeloid leukemia (AML) is a group of several different diseases, the treatment and outcome of which depend on several factors, including leukemia karyotype, patient age, and comorbid conditions. Despite advances in understanding the molecular biology of AML, its treatment remains challenging.
Elias J, Jabbour, Elihu, Estey, Hagop M, Kantarjian   +2 more
openaire   +2 more sources

Childhood Acute Myeloid Leukemia

Current Treatment Options in Oncology, 2008
Despite the use of intensive chemotherapy and hematopoietic stem cell transplantation, approximately one-third of children with acute myeloid leukemia (AML) still suffer relapse of their disease. It is unlikely that improvements in outcome can be achieved by further intensification of conventional chemotherapy.
openaire   +2 more sources

Decitabine in Acute Myeloid Leukemia

Seminars in Hematology, 2005
Standard induction chemotherapy, depending on patient tolerability, is at present the treatment of choice in patients with acute myeloid leukaemia (AML) under the age of 75 years. Since AML is a disease primarily of the elderly, a large proportion of patients do not receive this therapy; therefore, novel treatment modalities are warranted. In addition,
Lübbert, Michael, Minden, Mark
openaire   +3 more sources

Immunotherapy for acute myeloid leukemia

Current Oncology Reports, 2005
Immunotherapeutic strategies have become part of standard cancer treatment. Chimeric and humanized antibodies have demonstrated activity against a variety of tumors. Although the humanized anti-CD33 antibody HuM195 has only modest activity against overt acute myeloid leukemia (AML), it can eliminate minimal residual disease in acute promyelocytic ...
openaire   +2 more sources

Immunotherapy in Acute Myeloid Leukemia

Immunotherapy, 2013
Treatment of acute myeloid leukemia (AML) with current chemotherapy regimens is still disappointing, with overall survival rates of ≤ 40% at 5 years. It is now well established that AML cells can evade the immune system through multiple mechanisms, including the expression of the enzyme indoleamine 2,3 dioxygenase.
Mario, Arpinati, Antonio, Curti
openaire   +2 more sources

Immunotherapy in acute myeloid leukemia

Cancer, 2015
Despite the remarkable progress made in some leukemias such as CML and CLL, cytotoxic treatment for AML remains essentially unchanged over the last 4 decades. Several lines of evidence, including the graft versus leukemia effect associated with allogeneic hematopoietic stem cell transplantation (HSCT), suggest that immunotherapy is an active modality ...
Dolores A, Grosso, Rosemary C, Hess, Mark A, Weiss   +2 more
openaire   +2 more sources

Treatment of Acute Myeloid Leukemia

2010
The acute myeloid leukemias (AML) represent a heterogeneous group of malignancies derived from the pluripotent hematopoietic stem cell. These leukemias are generally characterized by genetic lesions that result in a combination of defects causing unregulated proliferation of cells and defects in cellular maturation (Gilliland and Griffin 2002).
Gibson, B, Perentesis, J., Alonzo, T.A., Kaspers, G.J.L.   +3 more
openaire   +3 more sources

Pediatric acute myeloid leukemia [PDF]

Expert Review of Anticancer Therapy, 2012
Pediatric acute myeloid leukemia (AML) is currently associated with survival rates as high as 70%. However, many events still occur, side effects are significant, and late effects occur and can even be life-threatening. Thus, the treatment of pediatric AML still needs further improvement.
openaire   +4 more sources

Decitabine for acute myeloid leukemia

Expert Review of Anticancer Therapy, 2012
Decitabine (Dacogen(®), Eisai Inc., NJ, USA) is a nucleoside analogue DNA methyltransferase inhibitor first synthesized and documented to have antileukemic efficacy over 40 years ago. Over the years, the dosing of decitabine has been refined, such that for acute myeloid leukemia, a 5-day schedule of 20 mg/m(2) is now commonly utilized.
openaire   +2 more sources